Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC-4881 in Familial Adenomatous Polyposis (Phase 1b-2 Multicenter Trial)
2026-525282-50-00Phase 2Authorised
- Sponsor
- Recursion Pharmaceuticals
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised trial in Colonic Adenomatous Polyposis comparing REC-4881 arm with Placebo arm (2 arms). Primary endpoints: Plasma pharmacokinetics (Part 1), Safety and tolerability (Part 2) and 1 more. Planned start Jul 2026; status: authorised.
02
Drugs
TAK-733
03
Conditions
Colonic Adenomatous Polyposis
Beyond the preview
Go deeper on 2026-525282-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525282-50-00.